July 25, 2014 12:04 AM ET


Company Overview of Pinnacle Biologics, Inc.

Company Overview

Pinnacle Biologics, Inc., a biopharmaceutical research and development company, develops and manufactures healthcare therapies for oncology and rare diseases. It specializes in revitalizing older brands and enabling newer therapies to maximize their potential for development as orphan drugs to treat cancer indications, in addition to those for which they have previously been approved. The company offers PHOTOFRIN (porfimer sodium), a photodynamic therapy drug that is indicated for the palliation of patients with obstructing esophageal cancer; the treatment of microinvasive endobronchial non-small-cell lung cancer; and the ablation of high-grade dysplasia in Barrett’s esophagus patients who d...

2801 Lakeside Drive

Suite 209

Bannockburn, IL 60015

United States

Founded in 2007





Key Executives for Pinnacle Biologics, Inc.

Age: 60
Vice-President of PDT Business Unit-Us
Compensation as of Fiscal Year 2014.

Pinnacle Biologics, Inc. Key Developments

FDA Approves Optiguide DCYL700 Fiber Optic Diffuser Series Flexible Fiber of Pinnacle Biologics, Inc

Concordia Healthcare Corp. announced that its subsidiary Pinnacle Biologics, Inc. was granted U.S. Food and Drug Administration (FDA) premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber. The Optiguide DCYL700 Fiber Optic Diffuser Series is a light delivery system used in Photodynamic Therapy (PDT) with PHOTOFRIN (porfimer sodium) approved for use in the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The system features a more flexible, narrower cylindrical diffuser design that may assist physicians by providing greater access to tumors located in the right upper lobe of the lung and by improving maneuverability in other potentially challenging anatomic areas of the bronchus.

Pinnacle Biologics, Inc. Reaches Agreement with U.S. Food and Drug Administration under Special Protocol Assessment for Phase 3 Clinical Trial on New Therapy to Treat Perihilar Cholangiocarcinoma

Concordia Healthcare Corp. announced that its subsidiary Pinnacle Biologics, Inc. has reached an agreement with the U.S. Food and Drug Administration (the 'FDA') under a special protocol assessment (the 'SPA') to enroll patients with an advanced form of bile duct cancer in a pivotal Phase 3 clinical trial. There is currently no approved therapy for this cancer type. The SPA is a written agreement between Pinnacle and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application submission. The clinical trial will study the efficacy and safety of photodynamic therapy ('PDT') with PHOTOFRIN(R) (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma (CCA) Bismuth type III/IV.

Similar Private Companies By Industry

Company Name Region
BioWa, Inc. United States
Exagen Diagnostics, Inc. United States
Biovest International Inc. United States
Southern Biosystems, Inc. United States
TheraKine Inc. United States

Recent Private Companies Transactions

December 24, 2013

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pinnacle Biologics, Inc., please visit www.pinnaclebiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.